Name
GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from Phase III lidERA Breast Cancer trial - Commentary by: Agatha Reyes, MD
Date & Time
Wednesday, December 3, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL